Åberg M

Robust humoral and cellular immune responses and low risk for reinfection at least 8 months following asymptomatic to mild COVID-19.

Havervall S, Ng H, Jernbom Falk A, ..., Hober S, Thålin C

J Intern Med 291 (1) 72-80 [2022-01-00; online 2021-09-27]

Category: Biochemistry Category: Health Funder: KAW/SciLifeLab National COVID program Research Area: Biobanks for COVID-19 research Research Area: Drug discovery and repurposing of drugs Research Area: High-throughput and high-content serology Research Area: Host cell systems biology and targets Research Area: Viral sequence evolution